SG Americas Securities
BHVN

SG Americas Securities’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

SG Americas Securities’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,786
Closed -$1.63M – 3518
2022
Q3 		$1.63M Sell
10,786
-9,396
-47% -$1.39M 0.02% 691
2022
Q2 		$2.94M Buy
20,182
+8,714
+76% +$1.11M 0.03% 532
2022
Q1 		$1.36M Sell
11,468
-8,210
-42% -$1.02M 0.01% 1204
2021
Q4 		$2.71M Sell
19,678
-336
-2% -$42.7K 0.01% 850
2021
Q3 		$2.78M Buy
20,014
+10,709
+115% +$1.34M 0.01% 990
2021
Q2 		$903K Buy
9,305
+472
+5% +$38.3K ﹤0.01% 1622
2021
Q1 		$604K Sell
8,833
-1,823
-17% -$147K ﹤0.01% 1885
2020
Q4 		$913K Sell
10,656
-3,327
-24% -$282K ﹤0.01% 1586
2020
Q3 		$909K Buy
13,983
+6,252
+81% +$410K 0.01% 1238
2020
Q2 		$565K Sell
7,731
-22,097
-74% -$1.18M ﹤0.01% 1985
2020
Q1 		$1.01M Buy
29,828
+27,596
+1,236% +$1.26M 0.01% 1282
2019
Q4 		$122K Buy
+2,232
New +$111K ﹤0.01% 2831
2019
Q2 		– Sell
-11,196
Closed -$576K – 3679
2019
Q1 		$576K Sell
11,196
-2,501
-18% -$108K 0.01% 1724
2018
Q4 		$507K Buy
+13,697
New +$494K ﹤0.01% 1857
2018
Q3 		– Sell
-4,826
Closed -$191K – 3691
2018
Q2 		$191K Buy
+4,826
New +$153K ﹤0.01% 2632

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

SG Americas Securities's BHVN Position: Q4 2022 in Review

SG Americas Securities sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 10,786 shares — an estimated $1.63M sold.

SG Americas Securities first reported a position in BHVN in Q2 2018 and held it in 15 quarters. The position peaked at $2.94M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • SG Americas Securities reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • SG Americas Securities sold 10,786 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.63M.
  • SG Americas Securities first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 15 quarters.
  • SG Americas Securities's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.94M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on SG Americas Securities's 13F filing for Q4 2022, filed 2 Feb 2023.